nalbuphine HCl ER
Phase 2/3Completed 0 watching 0 views this week๐ Rising
60
Development Stage
โ
Pre-clinicalโ
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Uremic Pruritus
Conditions
Uremic Pruritus, Pruritus
Trial Timeline
Sep 1, 2014 โ Jan 1, 2016
NCT ID
NCT02143973About nalbuphine HCl ER
nalbuphine HCl ER is a phase 2/3 stage product being developed by Trevi Therapeutics for Uremic Pruritus. The current trial status is completed. This product is registered under clinical trial identifier NCT02143973. Target conditions include Uremic Pruritus, Pruritus.
Hype Score Breakdown
Clinical
22
Activity
15
Company
5
Novelty
7
Community
8
Clinical Trials (3)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02174432 | Phase 2/3 | Completed |
| NCT02143973 | Phase 2/3 | Completed |
| NCT02373215 | Phase 1 | Completed |
Competing Products
15 competing products in Uremic Pruritus
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Crovalimab | Chugai Pharmaceutical | Phase 3 | 77 |
| Crovalimab | Chugai Pharmaceutical | Phase 3 | 77 |
| Ravulizumab | AstraZeneca | Pre-clinical | 23 |
| Eculizumab | AstraZeneca | Phase 3 | 77 |
| Iptacopan | Novartis | Phase 3 | 77 |
| Iptcaopan 200 mg | Novartis | Phase 3 | 77 |
| Iptacopan | Novartis | Phase 3 | 77 |
| MR13A9 + Placebo | Kissei Pharmaceutical | Phase 3 | 76 |
| MR13A9 + Placebo | Kissei Pharmaceutical | Phase 2 | 51 |
| CCX168 | Amgen | Phase 2 | 51 |
| Stage I:HSK21542 0.05 ฮผg/kg + Stage I:HSK21542 0.15 ฮผg/kg + Stage I:HSK21542 0.30 ฮผg/kg + Stage I:HSK21542 0.80 ฮผg/kg + Stage II:HSK21542 0.3 ฮผg/kg + Stage II:HSK21542 0.6 ฮผg/kg | Haisco Pharmaceutical Group | Phase 2 | 49 |
| Cemdisiran | Alnylam Pharmaceuticals | Phase 2 | 49 |
| cemdisiran + Placebos | Alnylam Pharmaceuticals | Phase 2 | 49 |
| Nalbuphine HCL ER | Trevi Therapeutics | Phase 1 | 28 |
| nalbuphine HCl ER tablets 60 mg BID + nalbuphine HCl ER tablets 120mg BID + Placebo tablets BID | Trevi Therapeutics | Phase 2/3 | 60 |
Other Products from Trevi Therapeutics
nalbuphine HCl ER tablets 90 mg BID + nalbuphine HCl ER tablets 180 mg BID + Placebo tablets BIDPhase 2/3
60
nalbuphine HCl ERPhase 2/3
60
nalbuphine HCl ER tablets 60 mg BID + nalbuphine HCl ER tablets 120mg BID + Placebo tablets BIDPhase 2/3
60
Nalbuphine ER Tablets + Placebo TabletsPhase 2/3
60
NAL ER + Placebo + NAL ER + NAL ERPhase 2
47